The microtubule-stabilizing agents epothilones A and B and their desoxy- derivatives induce mitotic arrest and apoptosis in human prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 1, 1999, Pages 41-52

  Sepp Lorenzino, L ^a   Balog, A ^a   Su, D S ^a   Meng, D ^a   Timaul, N ^a   Scher, H I ^a   Danishefsky, S J ^a   Rosen, N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Epothilones; Microtubules; Taxanes

Indexed keywords

EPOTHILONE A; EPOTHILONE B; PACLITAXEL;

APOPTOSIS; ARTICLE; DRUG RECEPTOR BINDING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEMBRANE STABILIZATION; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS SPINDLE; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE CULTURE; TUMOR GROWTH;

EID: 0033007667     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500282     Document Type: Article

References (42)

1. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer. J Natl Cancer Inst 1996; 88: 1623-1634.
2. van Brussel JP, Mickisch GH. Circumvention of multidrug resistance in genitourinary tumors. Int J Urol 1998; 5: 1-15.
3. Slovin SF et al. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol 1996; 23: 41-48.
4. Gerth K et al. Epothilones A and B: antifungal cytotoxic compounds from S. cellulosum (myxobacteria). J Antibiot 1996; 49: 560-563.
5. Höfle G et al. Epothilones A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl 1996; 35: 1567-1569.
6. Bollag DM et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-2333.
7. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997; 272: 2534-2541.
8. Giannakakou P et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-17125.
9. Balog A et al. Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone A series: some surprising observations regarding their chemical and biological properties. Tetrahedron Lett 1997; 38: 4529-4532.
10. Su D-S et al. Total synthesis of (-)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. Angew Chem Int Ed Engl 1997; 36: 757-759.
11. Hudes GR et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995; 41-45.
12. Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-3163.
13. Keren RS, Muggia FM. Response to estramustinc phosphate and paclitaxel in patients with advanced breast cancer: a phase I study. Semin Oncol 1997; S26-S29.
14. Pienta KJ, Naik H, Lehr JE. Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology 1996; 48: 164-170.
15. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997; S1572-S1577.
16. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-233.
17. Balog A et al. Total synthesis of (-)-epothilone A. Angew Chem Int Ed Engl 1996; 35: 2801-2803.
18. Nicolaou KC et al. Synthesis of epothilones A and B in solid and solution phase. Nature 1997; 387: 268-272.
19. Schinzer D et al. Total synthesis of (-)-epothilone A. Angew Chem Int Ed Engl 1997; 36: 523-524.
20. Yang Z et al. Total synthesis of epothilone A: the olefin metathesis approach. Angew Chem Int Ed Engl 1997; 36: 166-168.
21. Giaretti W, Nusse M. Light scatter of isolated cell nuclei as a parameter discriminating the cell-cycle subcompartments. Methods Cell Biol 1994; 41: 389-400.
22. Nusse M et al. Flow cytometric detection of mitotic cells using bromodeoxyuridine/DNA technique in combination with 90 degrees and forward scatter measurements. Cytometry 1990; 11: 813-821.
23. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
24. Schiff BP, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-1565.
25. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997; 17: 96-104.
26. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5: S3-S6.
27. Sorger PK, Dobles M, Tournebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997; 9: 807-814.
28. Belani CP. Paclitaxel/carboplatin in the treatment of non-small-cell lung cancer. Oncology (Huntingt) 1998; 12: 74-79.
29. Bunn PJ. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol 1997; 24: S12153-S12162.
30. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 1997; 24: S1311-S1318.
31. Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non-small-cell lung cancer. Curr Probl Cancer 1998; 22: 83-132.
32. Rowinsky EK. The development clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48:353-374.
33. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol 1997; 24: S1319-S1326.
34. Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy 1997; 17: 110S-125S.
35. D'Andrea GM, Seidman AD. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol 1997; 24: S1327-S1344.
36. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 1998; 91: 783-972.
37. Kearns CM. Pharmacokinetics of the taxanes. Pharmacotherapy 1997; 17: 105S-109S.
38. Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 1997; 94: 10560-10564.
39. Laing N et al. Interaction of estramustine with tubulin isotypes. Biochemistry 1997; 36: 871-878.
40. Sepp-Lorenzino L et al. A peptidomimetic inhibitor of farnesyl:-protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
41. Moasser MM et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-1374.
42. Sepp-Lorenzino L et al. Farnesyl:protein transferase inhibitors (FTIs) as potential agents for the management of prostate cancer. 1998; (submitted).